G
Originally published by Ghafla! (Entertainment)entertainment
September 30, 2025
1h ago
Millions in LMICs to Access Affordable HIV Prevention Injection
Millions of people in low- and middle-income countries (LMICs) are set to benefit from a groundbreaking HIV prevention drug that will soon be available at a fraction of its original cost. On 24 September 2025 in New York, global health leaders announced that lenacapavir, a powerf..
✨ Key Highlights
Millions in low- and middle-income countries (LMICs) are set to gain access to an affordable, long-acting injectable HIV prevention drug called lenacapavir, hailed as a potential game-changer. This breakthrough follows new pricing agreements announced in New York on September 24, 2025.
- The generic version of lenacapavir, produced by Hetero Labs, will cost approximately $40 per patient annually (roughly KSh 5,000).
- The Bill & Melinda Gates Foundation partnered with Hetero Labs and committed over $80 million in upfront funding.
- A single injection provides six months of HIV protection, with initial generic supplies expected by 2027, and limited early access in LMICs possible by late 2025.
Continue Reading
Read the complete article from Ghafla! (Entertainment)
